ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 112 filers reported holding ACLARIS THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.89 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $354,130 | -20.2% | 51,698 | +20.9% | 0.00% | – |
| Q2 2023 | $443,504 | -21.5% | 42,768 | -38.8% | 0.00% | – |
| Q1 2023 | $565,191 | -55.8% | 69,863 | -13.9% | 0.00% | – |
| Q4 2022 | $1,277,609 | +13.1% | 81,118 | +13.0% | 0.00% | – |
| Q3 2022 | $1,130,000 | -16.3% | 71,817 | -25.7% | 0.00% | – |
| Q2 2022 | $1,350,000 | +150.0% | 96,697 | +208.8% | 0.00% | – |
| Q1 2022 | $540,000 | -38.8% | 31,314 | -48.4% | 0.00% | – |
| Q4 2021 | $882,000 | +121.1% | 60,658 | +173.8% | 0.00% | – |
| Q3 2021 | $399,000 | +52.3% | 22,152 | +48.2% | 0.00% | – |
| Q2 2021 | $262,000 | – | 14,943 | +33861.4% | 0.00% | – |
| Q3 2020 | $0 | -100.0% | 44 | -99.0% | 0.00% | – |
| Q2 2020 | $7,000 | +600.0% | 4,388 | +391.9% | 0.00% | – |
| Q1 2020 | $1,000 | -97.1% | 892 | -95.0% | 0.00% | – |
| Q4 2019 | $35,000 | +29.6% | 18,000 | -27.0% | 0.00% | – |
| Q3 2019 | $27,000 | -81.9% | 24,671 | -63.7% | 0.00% | – |
| Q2 2019 | $149,000 | -79.4% | 67,935 | -43.8% | 0.00% | – |
| Q1 2019 | $725,000 | +116.4% | 120,971 | +166.8% | 0.00% | – |
| Q4 2018 | $335,000 | +39.6% | 45,345 | +174.1% | 0.00% | – |
| Q3 2018 | $240,000 | +112.4% | 16,542 | +190.7% | 0.00% | – |
| Q2 2018 | $113,000 | -41.8% | 5,690 | -48.6% | 0.00% | – |
| Q1 2018 | $194,000 | +5.4% | 11,063 | +49.0% | 0.00% | – |
| Q4 2017 | $184,000 | -94.6% | 7,426 | -94.4% | 0.00% | -100.0% |
| Q3 2017 | $3,435,000 | +47.7% | 133,103 | +55.2% | 0.00% | – |
| Q2 2017 | $2,326,000 | +3713.1% | 85,776 | +4102.6% | 0.00% | – |
| Q1 2017 | $61,000 | +27.1% | 2,041 | +15.9% | 0.00% | – |
| Q4 2016 | $48,000 | +220.0% | 1,761 | +190.6% | 0.00% | – |
| Q3 2016 | $15,000 | +400.0% | 606 | +256.5% | 0.00% | – |
| Q2 2016 | $3,000 | -25.0% | 170 | +22.3% | 0.00% | – |
| Q4 2015 | $4,000 | – | 139 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |